Pharmacokinetics and Bioequivalence Study of Levodopa and Benserazide Tablets in Healthy Chinese Subjects Under Fasting and High‐Fat Meal Conditions
Clinical Pharmacology in Drug Development · 2026-07 · 15 (7)
DOI: 10.1002/cpdd.70080 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 20.07.2026. Verfasst von Yufei Liang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Phase I Clinical Trials Center, Hebei PetroChina Central Hospital, Langfang, China. Hauptthemen laut MEDLINE: Benserazide, Diet, High-Fat, Fasting, Levodopa. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Beijing Foyou Pharmaceutical Co., Ltd., S&T Program of Langfang.
Abstract (Originalsprache)
Levodopa and benserazide tablets (LBTs) are a combined preparation of levodopa (L‐DP), a dopamine precursor, and benserazide (BZ), a peripheral dopa decarboxylase inhibitor, used for the treatment of Parkinson's disease, which predominantly affects middle‐aged and elderly individuals. This study employed a single‐center, randomized, open‐label, two‐formulation, three‐period, three‐sequence, partially replicated (reference formulation only) clinical study design to evaluate the pharmacokinetics and bioequivalence of the test and reference formulations of LBT administered orally to 96 healthy Chinese subjects under fasting or fed conditions. After fasting for at least 10 h and abstaining from water for 1 h, subjects received one tablet of either the test or reference formulation with 240 mL of warm water on Days 1, 8, and 15 of the study, either in the fasting state or 30 min after starting a high‐fat meal. Plasma drug concentrations were determined using an ultra‐high performance liquid chromatography‐tandem mass spectrometry method. The 90% confidence intervals of the geometric mean ratios for the pharmacokinetic parameters C max , AUC 0‐t , and AUC 0‐∞ met the bioequivalence criteria, indicating that the test formulation is bioequivalent to the reference formulation in healthy Chinese adult subjects. No serious adverse events were reported.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phase I Clinical Trials Center, Hebei PetroChina Central Hospital, Langfang, China.
- Department of Clinical Research, Beijing Foyou Pharmaceutical Co., Ltd., Beijing, China.
Förderung
- Beijing Foyou Pharmaceutical Co., Ltd.
- S&T Program of Langfang
Zitieren
APA
Liang, Y., Wang, Y., Shi, R., Pei, Y., Zhao, X., Wang, Q., Ren, Y., Xie, Z., & Zhao, K. (2026). Pharmacokinetics and Bioequivalence Study of Levodopa and Benserazide Tablets in Healthy Chinese Subjects Under Fasting and High‐Fat Meal Conditions. Clinical Pharmacology in Drug Development, 15(7). https://doi.org/10.1002/cpdd.70080
Vancouver
Liang Y, Wang Y, Shi R, Pei Y, Zhao X, Wang Q, et al. Pharmacokinetics and Bioequivalence Study of Levodopa and Benserazide Tablets in Healthy Chinese Subjects Under Fasting and High‐Fat Meal Conditions. Clinical Pharmacology in Drug Development. 2026;15(7). doi:10.1002/cpdd.70080
BibTeX
@article{Liang2026,
author = {Liang, Yufei and Wang, Yanchao and Shi, Rui and Pei, Yingzi and Zhao, Xiao and Wang, Qian and Ren, Yanping and Xie, Zekang and Zhao, Kexin},
title = {Pharmacokinetics and Bioequivalence Study of Levodopa and Benserazide Tablets in Healthy Chinese Subjects Under Fasting and High‐Fat Meal Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cpdd.70080}
}
EUVIMED